RECKITTBEN Reckitt Benckiser(bangladesh) Ltd.
Pharmaceuticals & Chemicals
Tk 3,205.2 as of 2026-11-12 14:00:00
Data completeness 100%
Score breakdown
Weights: consistency 30%, profitability 30%, solvency 20%, valuation 20%; then risk flags add or subtract points. Full method
Why this score
Strengths
- Consistency Paid a dividend every year (5/5)
- Profitability Average ROE 67.95% (efficient: above 15%)
- Solvency Practically debt-free (loan risk cannot hurt it)
Concerns
- Valuation Trades at 23.57x book value (NAV Tk 135.96, price Tk 3205.2)
- Valuation Price is 341% above the Graham fair value (Tk 727.3)
Notes
- Consistency EPS rose in 2 of 4 years (mixed)
- Valuation P/E 17.83 is fair
Risk flags
- Thin trading (last day ~Tk 0.06 cr)
- Within 0.75% of its 52-week low: check WHY before treating it as cheap
Valuation
52-week range
0.8% above the low, 13.4% below the high. Near the low is only interesting if profit is intact (see concerns above) and the fall has a temporary cause.
Quality and growth
Dividends and safety
Size, liquidity and ownership
Shareholding
- Sponsor/director 83%
- Institution 6.8%
- Foreign 0%
- Govt 3.8%
- Public 6.5%
Audited history
| Year | EPS (Tk) | NAV/share | Net profit (cr) | Cash div % | Bonus % |
|---|---|---|---|---|---|
| 2021 | 171.03 | 200.65 | 81 | 1,650 | 0 |
| 2022 | 139.5 | 176.8 | 66 | 980 | 0 |
| 2023 | 173.65 | 252.69 | 82 | 550 | 0 |
| 2024 | 159.17 | 350.64 | 75 | 3,330 | 0 |
| 2025 | 172.93 | 187.58 | 82 | 1,730 | 0 |
Fiscal year ends December. EPS, NAV and profit are as audited by the company and published by DSE. Financials last fetched: 14/11/2026.
Shariah screen (partial)
Business screen and the debt ratio (loans / market cap 0%, limit 33%) are automated. Interest income (under 5% of revenue) and cash/investment ratios must be checked in the annual report.
Educational, not investment advice. Verify on DSE and StockNow before making any decision.